Sp946
EVALUATION OF GASTROPARESIS
Date
May 20, 2024
Tracks
Related Products
SPECIFIC PATIENT PHENOTYPING IN GASTRODUODENAL DISORDERS USING GASTRIC ALIMETRY® WITH COMPARISON TO GASTRIC EMPTYING SCINTIGRAPHY
INTRODUCTION: Patients with upper gastrointestinal (UGI) symptoms of abdominal pain, nausea, vomiting, and bloating often complain within the postprandial period…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
MULTIOMIC CHARACTERIZATION OF GASTRIC MUSCULARIS PROPRIA IN IDIOPATHIC GASTROPARESIS
BACKGROUND: Idiopathic gastroparesis (IG) is an increasingly prevalent subtype of gastroparesis and causes significant morbidity and decreased quality of life…
AGA Functional Dyspepsia, Nausea and Vomiting
SOCIETY: AGA